全文获取类型
收费全文 | 294篇 |
免费 | 8篇 |
国内免费 | 7篇 |
专业分类
儿科学 | 6篇 |
妇产科学 | 3篇 |
基础医学 | 15篇 |
口腔科学 | 2篇 |
临床医学 | 28篇 |
内科学 | 80篇 |
皮肤病学 | 1篇 |
神经病学 | 9篇 |
特种医学 | 9篇 |
外科学 | 16篇 |
综合类 | 25篇 |
预防医学 | 1篇 |
眼科学 | 2篇 |
药学 | 99篇 |
中国医学 | 12篇 |
肿瘤学 | 1篇 |
出版年
2022年 | 3篇 |
2020年 | 4篇 |
2019年 | 5篇 |
2018年 | 4篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 3篇 |
2014年 | 11篇 |
2013年 | 26篇 |
2012年 | 8篇 |
2011年 | 7篇 |
2010年 | 8篇 |
2009年 | 6篇 |
2008年 | 8篇 |
2007年 | 9篇 |
2006年 | 9篇 |
2005年 | 8篇 |
2004年 | 8篇 |
2003年 | 7篇 |
2002年 | 10篇 |
2001年 | 8篇 |
2000年 | 5篇 |
1999年 | 11篇 |
1998年 | 2篇 |
1997年 | 11篇 |
1996年 | 4篇 |
1995年 | 8篇 |
1994年 | 9篇 |
1993年 | 8篇 |
1992年 | 5篇 |
1991年 | 9篇 |
1990年 | 8篇 |
1989年 | 8篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1986年 | 10篇 |
1985年 | 13篇 |
1984年 | 2篇 |
1983年 | 5篇 |
1982年 | 4篇 |
1981年 | 7篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1977年 | 1篇 |
1976年 | 2篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有309条查询结果,搜索用时 15 毫秒
1.
2.
Effects of chlorpromazine as a systemic vasodilator during cardiopulmonary bypass in neonates 总被引:1,自引:0,他引:1
Yutaka Imoto Hideaki Kado Munetaka Masuda Hisataka Yasui 《The Japanese Journal of Thoracic and Cardiovascular Surgery》2002,50(6):241-245
OBJECTIVES: Vasodilator use during cardiopulmonary bypass is important in pediatric cardiac surgery, but the full range of their effects on hemodynamics remains to be clarified. We studied the effects of chlorpromazine, a potent alpha-blocking agent, in neonates. METHODS: Subjects were 60 neonates undergoing arterial switch operations for complete transposition of the great arteries with an intact ventricular septum. Of these, 37 received 2.1 to 6.5 mg/kg of chlorpromazine during cardiopulmonary bypass (CPZ group) and 23 received no vasodilator (control group). We then compared hemodynamic parameters between groups during and early after surgery. RESULTS: The systemic vascular resistance index and mean arterial pressure during cardiopulmonary bypass were significantly lower in the CPZ group (p < 0.05), but systolic pressure 15 minutes after cessation of cardiopulmonary bypass did not differ between groups. The rise in peripheral temperature during rewarming after hypothermia was significantly higher and the acid-base status 40 minutes after cardiopulmonary bypass less acidotic in the CPZ group. Urine output during cardiopulmonary bypass was higher in the CPZ group. CONCLUSIONS: Chlorpromazine effectively counteracts systemic vasoconstriction induced by cardiopulmonary bypass without serious side effects in neonatal cardiac surgery. 相似文献
3.
A group of 21 patients with various degrees of chronic obstructive pulmonary disease underwent radionuclide ventriculography with hemodynamic monitoring to assess the extent to which pulmonary artery pressures and pulmonary vascular resistance can be lowered by the vasodilator molsidomine. Molsidomine (N-carboxy-3-morpholino-sydnonimin-ethylester) is similar to nitroglycerin in its mode of action. After hemodynamic and radionuclide data acquisition, at rest and during submaximal exercise in the steady state, 2 mg molsidomine was injected intravenously. Rest and exercise measurements were repeated 45 min after molsidomine injection. In patients with mild to moderate disease (group 1), pulmonary artery resting pressures decreased by 12% (p less than 0.05) at rest by 22% (p less than 0.01) during exercise after the administration of the drug. Total pulmonary resistance during exercise decreased significantly (p less than 0.01) as a result of marked decrease of pulmonary artery pressure (PAP) compared with a minimal decrease in cardiac index (CI). In patients with severe disease (group 2), only the resting values of PAP decreased while the relationship between pressure and flow was unchanged. During the exercise period, the preload parameters of the right and left ventricles decreased by an average of 30%. With regard to gas exchange, only the arterial PO2 at rest decreased slightly but significantly (p less than 0.05) after molsidomine, while the coefficient of oxygen delivery was not affected by the drug. However, in four patients arterial PO2 was markedly reduced by the drug. Right ventricular ejection fraction increased significantly (p less than 0.01) both at rest and during exercise in group 1 and during exercise in group 2 after administration of molsidomine.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
4.
血管扩张药桂哌齐特的合成研究 总被引:6,自引:0,他引:6
目的:合成桂哌齐特。方法:以3,4,5-三甲氧基肉桂酸为起始原料,于室温下制成酰氯后与[(1-四氢吡咯羰基)甲基]哌嗪进行取代反应,再与顺丁烯二酸成盐即制得桂哌齐特。结果:经氯代、胺化和成盐3步反应合成桂哌齐特,总收率为36.1%。结论:该反应途径简单温和,适合工业化生产。 相似文献
5.
H H Al-Sa'doni I L Megson S Bisland A R Butler F W Flitney 《British journal of pharmacology》1997,121(6):1047-1050
- A study has been made of the effect of neocuproine, a specific Cu(I) chelator, on vasodilator responses of rat isolated perfused tail artery to two nitrosothiols: S-nitroso-N-acetyl-D,L-penicillamine (SNAP) and S-nitroso-glutathione (GSNO).
- Bolus injections (10 μl) of SNAP or GSNO (10−7–10−3 M) were delivered into the lumen of perfused vessels pre-contracted with sufficient phenylephrine (1–7 μM) to develop pressures of 100–120 mmHg. Two kinds of experiment were made: SNAP and GSNO were either (a) pre-mixed with neocuproine (10−4 M) and then injected into arteries; or (b) vessels were continuously perfused with neocuproine (10−5 M) and then injected with either pure SNAP or GSNO.
- In each case, neocuproine significantly attenuated vasodilator responses to both nitrosothiols, although the nature of the inhibitory effect differed in the two types of experiment. We conclude that the ability of exogenous nitrosothiols to relax vascular smooth muscle in our ex vivo model is dependent upon a Cu(I) catalyzed process. Evidence is presented which suggests that a similar Cu(I)-dependent mechanism is responsible for the release of NO from endogenous nitrosothiols and that this process may assist in maintaining vasodilator tone in vivo.
6.
Sorin Giusca M.D. Ruxandra Jurcut M.D. Ph.D. Ioan Mircea Coman M.D. Ph.D. Ioana Ghiorghiu M.D. Ph.D. Daniela Catrina M.D. Bogdan A. Popescu M.D. Ph.D. Laura Dima M.D. Carmen Ginghina M.D. Ph.D. 《Echocardiography (Mount Kisco, N.Y.)》2013,30(1):17-26
Introduction: We followed patients with pulmonary arterial hypertension (PAH) receiving specific vasodilator therapy and tested for predictors of clinical outcome. Methods: Thirty‐two patients (mean age 39 ± 15 years, 22 women, diagnosed with pulmonary hypertension; PH): 29 with PAH and 3 patients with inoperable chronic thromboembolic PH received therapy with either bosentan, sildenafil, or both and were evaluated with clinical parameters, biomarkers (B‐type natriuretic peptide values), and echocardiography before receiving specific medication and every 3 months thereafter. A right heart catheterization was performed at baseline. A composite endpoint of death, worsening of functional class, or the need of a second vasodilator agent was used to define the clinical nonresponders. Results: Patients were followed for 14 months (7.5–21). The endpoint was reached by 15 patients: four patients died (two idiopathic PAH and two PAH in context of Eisenmenger syndrome), seven patients showed 1 functional class worsening, and four patients needed to be switched to combination therapy. Patients who remained clinically stable or improved had at baseline a better cardiac output with a less remodeled right ventricle (RV) and better functioning RV (all P < 0.05). A RV fractional area change (RVFAC) lower than 25.7% and a RV global strain value higher than ?13.4% predict with 87% sensitivity and 83% specificity (AUC 87.3%, P = 0.001) and 73% sensitivity and 91% specificity (AUC 84.2%, P = 0.003), respectively, patients who will deteriorate clinically under specific vasodilator therapy. A multivariate model showed RVFAC to be the only independent predictor of the endpoint with a HR of 0.87 (0.8–0.96), P = 0.007. Conclusions: Over an average period of 1 year, almost half of patients showed signs of clinical deterioration despite specific vasodilator therapy. Parameters of right ventricular morphology and function had prognostic value in these patients. 相似文献
7.
8.
9.
10.